Glimiprex MF 4mg/500mg Tablet is a combination oral antidiabetic medication containing Glimepiride 4mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The synergistic action of these two agents helps in achieving better glycemic regulation compared to monotherapy. Glimiprex MF is typically prescribed as an adjunct to diet and exercise to optimize blood glucose levels in patients inadequately controlled with either agent alone. It is important to monitor renal function before and during treatment due to the risk of metformin-associated lactic acidosis, especially in patients with renal impairment. Common adverse effects may include hypoglycemia, gastrointestinal disturbances such as nausea, vomiting, and diarrhea, and rarely, allergic reactions. Dose adjustments should be individualized based on therapeutic response and tolerability. This combination therapy offers a convenient and effective option for improving glycemic control in type 2 diabetes, thereby reducing the risk of long-term complications associated with hyperglycemia.